Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 26, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7...
-
Oct 23, 2017
Boston Scientific (NYSE: BSX) today announced key data that will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular...
-
Oct 4, 2017
Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Desiree Ralls-Morrison as senior vice president, general counsel and corporate secretary. Ralls-Morrison will join...
-
Oct 2, 2017Acquisition to Strengthen Company's Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon...
-
Oct 2, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2017 on Thursday, October...
-
Sep 25, 2017
Boston Scientific (NYSE: BSX) has launched the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the...
-
Sep 19, 2017Data Presented at Heart Failure Society of America's 21st Annual Scientific Meeting Demonstrate Alert Improves Heart Failure Risk Prediction
Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the...
-
Sep 18, 2017Patients with Severe Asthma Show Sustained Clinical Improvement
Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...
-
Aug 28, 2017
Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2017 in New York City. Mike Mahoney, chairman and chief executive...
-
Aug 21, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, 2017 in Boston. Susie Lisa, vice president, Investor Relations, will...
-
Jul 31, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity Growth Conference on August 9, 2017 in Boston. Boston Scientific investor relations representatives,...
-
Jul 27, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...
-
Jul 5, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at
-
Jun 27, 2017
Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...
-
Jun 6, 2017Industry's First MR-Conditional Directional DBS System with Stimulation Visualization
Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...
-
May 24, 2017Results from Evaluation of Real-World Patients Presented at American Thoracic Society International Conference
Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...
-
May 17, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
May 16, 2017Acquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 12, 2017Largest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...
-
May 12, 2017Analyses Evaluated the Impact of Ethnicity, Gender and Income on Cardiovascular Outcomes
New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...
-
May 11, 2017Late-Breaker Data Presented at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced results from the U.S. post-market approval study evaluating 'real-world' patients implanted with the Subcutaneous Implantable Defibrillator (S-ICD)...
-
May 10, 2017Pivotal Data From REPRISE III and EWOLUTION Among Four Late-breaking Clinical Trials to be Presented
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including four late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program,...
-
May 9, 2017New Devices Combine Longest-Lasting Battery Technology, Therapy Optimization and HeartLogic™ Heart Failure Diagnostics
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization...
-
May 3, 2017Late-Breaking Clinical Trials Feature Subcutaneous Implantable Defibrillator and WATCHMAN™ Left Atrial Appendage Closure Device
Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of...